Methods of Monitoring Responsiveness to Anti-SMAD7 Therapy

摘要

Methods for monitoring whether a subject will be sensitive or resistant to treatment with an anti-SMAD7 therapy are disclosed. The methods are based on the determining of the amount of CCR9+ FOXP3+ T cells, CCR9+ IFN-gamma+ T cells, CCR9+ IL17A+ T cells, FOXP3+ T cells, IFN-gamma+ T cells, and/or IL17A+ T cells in a sample from the subject. Measurement of T cell populations may be determined by flow cytometry, immunohistochemistry, and/or ELISA.

主权项

1. A method for determining the responsiveness of a subject having Inflammatory Bowel Disease (IBD) to treatment with at least one anti-SMAD7 therapy, the method comprising:
determining the amount of at least one cell population selected from the group consisting of: CCR9+ FoxP3+ T cells, CCR9+ IFN-gamma+ T cells, CCR9+ IL17A+ T cells, FoxP3+ T cells, IFN-gamma+ T cells and IL17A+ T cells, in at least one sample obtained from the subject, wherein, increased amounts of the cell population CCR9+ FoxP3+ T cells, and/or decreased amounts of at least one of the cell populations CCR9+ IFN-gamma+ T cells, CCR9+ IL17A+ T cells, FoxP3+ T cells, IFN-gamma+ T cells and IL17A+ T cells, in the at least one sample relative to a known control level of the at least one cell population is predictive of responsiveness of the subject having IBD to the anti-SMAD7 therapy.